Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 41, n° 6
pages 962-969 (décembre 1999)
Doi : 10.1016/S0190-9622(99)70254-9
accepted : 8 June 1999
S-100 protein in peripheral blood: A marker for melanoma metastases : A prospective 2-center study of 570 patients with melanoma
 

Peter Kaskel, MDa,c*, Carola Berking, MDc*, Silvia Sanderb, Matthias Volkenandt, MDc, Ralf Uwe Peter, MDa, Gertraud Krähn, MDa,c
Ulm and Munich, Germany 
From the Departments of Dermatologya and Biometry and Medical Documentation,b University of Ulm; and the Department of Dermatology, University of Munich.c *Peter Kaskel and Carola Berking contributed equally to this work 

Abstract

Background: S-100 protein, commonly used in the immunohistochemical diagnosis of malignant melanoma and melanoma metastases, has recently been introduced as a tumor marker in peripheral blood. Objective: This prospective, observational, 2-center study evaluates S-100 in peripheral blood of patients with melanoma as a marker for metastasis. Methods: With application of an immunoluminometric assay, S-100 levels in 1396 samples of 570 patients with melanoma and 53 control subjects were measured in a blinded manner. Results: The cut-off level for patients with melanoma without medical history of metastases versus patients with newly occurring lymph node, visceral, and/or brain metastases was 0.114 μg/L, with a sensitivity of 94% (95% confidence interval, 86.4%-98.5%) and a specificity of 91% (95% confidence interval, 87.7%-93.6%). False-negative results included patients with unknown primary melanoma and those with amelanotic melanoma metastases. Conclusion: The data suggest that S-100 in the peripheral blood of patients with melanoma could serve as a marker indicating new melanoma metastases and could help to monitor the course of the disease. (J Am Acad Dermatol 1999;41:962-9.)

The full text of this article is available in PDF format.

 Reprint requests: Gertraud Krähn, MD, Department of Dermatology, University of Ulm, Oberer Eselsberg 40 (BWK), D-89081 Ulm/Donau, Germany.
 0190-9622/99/$8.00 + 0  16/1/100561



© 1999  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline